Crohn’s Disease — Clinical Documentation Guide (2026)

This Clinical Documentation Guide (CDG) provides AAPC/AHIMA-credentialed coders and CDI specialists with comprehensive coding, clinical, and documentation guidance for Crohn’s disease (ICD-10-CM category K50). Content reflects FY2026 ICD-10-CM guidelines (effective October 1, 2025 – September 30, 2026) and incorporates current clinical practice standards from the Crohn’s & Colitis Foundation and the American College of Gastroenterology (ACG). Use this guide to ensure accurate diagnosis code assignment, appropriate CDI query triggers, and defensible documentation for Crohn’s disease encounters across all care settings.

🔍 1. Definition

Crohn’s disease is a chronic, relapsing-remitting inflammatory bowel disease (IBD) characterized by transmural (full-thickness) inflammation that can affect any segment of the gastrointestinal tract from the mouth to the anus. Unlike ulcerative colitis, which is limited to the colonic mucosa, Crohn’s disease features skip lesions — areas of diseased bowel separated by segments of normal-appearing tissue — and may involve multiple layers of the intestinal wall, leading to fibrosis, stricture formation, and fistulization, as described by the Crohn’s & Colitis Foundation.

The most commonly affected area is the terminal ileum (ileitis or regional enteritis), but the disease frequently extends into the colon (ileocolitis). The transmural nature of the inflammation gives rise to characteristic complications including fistulae, abscesses, strictures, and bowel obstruction, all of which have distinct ICD-10-CM coding implications. According to StatPearls (NCBI), Crohn’s disease affects approximately 780,000 Americans, with peak incidence in the second and third decades of life.

Disease activity is classified as:

• Remission: No active symptoms; inflammatory markers normal
• Mild-to-moderate active: Ambulatory patients with diarrhea, abdominal pain, weight loss <10%
• Moderate-to-severe active: Failed mild therapy or features of fever, significant weight loss, anemia, obstruction
• Severe/fulminant: Persistent symptoms despite corticosteroids, high fever, rebound tenderness, cachexia

🗂️ 2. Alternative Terminology

Crohn’s disease is documented under a variety of clinical, historical, and lay terms. Coders must recognize all of the following as mapping to K50.xx:

🩺 3. Signs & Symptoms

Crohn’s disease presents with a wide spectrum of gastrointestinal and extraintestinal manifestations. The Crohn’s & Colitis Foundation identifies the following core symptoms:

Gastrointestinal Symptoms

• Persistent diarrhea — often watery; may be bloody if colonic involvement
• Abdominal pain and cramping — typically right lower quadrant (terminal ileal disease); may be diffuse
• Rectal bleeding — more common in colonic Crohn’s; may cause iron-deficiency anemia
• Nausea and vomiting — particularly with stricturing disease/obstruction
• Urgency and tenesmus — with rectal/colonic involvement
• Weight loss and malnutrition — due to malabsorption, food avoidance, elevated metabolic demand
• Fever — with active inflammation, abscess, or fistula
• Perianal disease — fissures, fistulae, skin tags, abscesses

Extraintestinal Manifestations

• Arthropathy — peripheral or axial (enteropathic arthritis, M07.6x)
• Dermatologic: Erythema nodosum (L52), pyoderma gangrenosum, psoriasis (L40.5)
• Ocular: Uveitis/iritis (H20.01), episcleritis, scleritis
• Hepatobiliary: Primary sclerosing cholangitis (K73.2), fatty liver, cholelithiasis
• Metabolic: Osteopenia/osteoporosis (from steroid use and malabsorption), nephrolithiasis
• Hematologic: Anemia (iron deficiency, B12/folate deficiency, anemia of chronic disease)

🧭 4. Differential Diagnosis

Accurate distinction between Crohn’s disease and other conditions is essential for correct ICD-10-CM code assignment. The following table summarizes key differentials with distinguishing features and relevant codes:

📋 5. Clinical Indicators for Coders/CDI

The following indicators, when present in physician documentation, laboratory values, or diagnostic reports, support assignment of a Crohn’s disease diagnosis and may trigger CDI queries for greater specificity:

🦴 6. Anatomy & Pathophysiology

Understanding the anatomic and pathophysiologic features of Crohn’s disease is essential for accurate location-based coding and complication identification.

Anatomic Sites and ICD-10-CM Location Mapping

• Small intestine (K50.0x): Includes duodenum, jejunum, and ileum. The terminal ileum is the most common site (~70% of cases). Presents with right lower quadrant pain, diarrhea, and malabsorption.
• Large intestine (K50.1x): Involves cecum, ascending, transverse, descending, or sigmoid colon, or rectum. May present with bloody stool, urgency, and perianal disease.
• Both small and large intestine (K50.8x): Ileocolitis — the most common overall pattern (~40–50% of all CD patients) per StatPearls. Involves simultaneous disease in ileum and colon.
• Unspecified (K50.9x): Use only when provider documentation does not specify location and a query is not feasible.

Pathophysiology

Crohn’s disease results from a dysregulated immune response to intestinal microbiota in genetically susceptible individuals, as described by StatPearls (NCBI). Key pathophysiologic mechanisms include:

• Mucosal barrier dysfunction: Impaired epithelial tight junctions allow bacterial translocation, triggering innate immune activation
• T-helper cell dysregulation: Predominantly Th1 and Th17 pathways drive chronic inflammation via TNF-α, IL-12, IL-23 — the basis for biologic therapy targets
• Transmural inflammation: Unlike UC (mucosal only), CD involves all layers: mucosa → submucosa → muscularis propria → serosa
• Granuloma formation: Non-caseating granulomas are pathognomonic but present in only ~30–50% of biopsies
• Fibrosis and stricture: Chronic inflammation activates myofibroblasts → collagen deposition → luminal narrowing → obstructive symptoms
• Fistula formation: Transmural ulcers penetrate serosa → form sinus tracts → connect to adjacent bowel, bladder, vagina, or skin

💊 7. Medication Impact / Treatment

Medications used in Crohn’s disease management directly affect coding, CDI documentation requirements, and HCC risk stratification. The ACG Clinical Guidelines for Crohn’s Disease Management stratify therapy by disease severity and location.

Medication Categories

• Aminosalicylates (5-ASA): Sulfasalazine, mesalamine — limited role in CD; primarily used for colonic disease
• Corticosteroids: Prednisone, budesonide — for induction of remission in mild-moderate disease; long-term use associated with osteoporosis, adrenal suppression (code separately)
• Immunomodulators: Azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate — for maintenance of remission; thiopurine metabolite monitoring required
• Biologics (TNF-α inhibitors): Infliximab (Remicade®, J1745), adalimumab (Humira®), certolizumab pegol (Cimzia®) — standard of care for moderate-to-severe CD; require documentation of indication, dosing, and clinical response
• Biologics (IL-12/23 inhibitor): Ustekinumab (Stelara®, J3357) — FDA-approved for moderate-to-severe CD; subcutaneous or IV induction
• Biologics (Integrin inhibitor): Vedolizumab (Entyvio®, J3380) — gut-selective; IV infusion; HCPCS J3380
• Biologics (IL-23 inhibitor): Risankizumab (Skyrizi®, J7999) — newer biologic for moderate-to-severe CD; IV induction followed by SQ maintenance
• JAK inhibitors: Upadacitinib (Rinvoq®) — oral small molecule; increasingly used for moderate-to-severe CD
• Antibiotics: Metronidazole, ciprofloxacin — for perianal disease, fistulae, abscesses

Coding Impact of Biologic Therapy

When a patient is receiving biologic therapy for Crohn’s disease, coders should verify:

• HCPCS code for the specific biologic agent (J1745, J3357, J3380, J7999) is separately reported for the infusion encounter
• Infusion administration code (CPT 96413, 96415) is reported with the biologic J-code
• Long-term use of immunosuppressants should be captured with Z79.899 (long-term use of other medication) when relevant
• Biologic use combined with Crohn’s disease supports HCC 35 mapping and higher risk scores

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 8. ICD-10-CM Guidelines (FY2026)

The following guidelines govern ICD-10-CM code assignment for Crohn’s disease under FY2026 ICD-10-CM Official Guidelines for Coding and Reporting. Category K50 covers all Crohn’s disease (regional enteritis) and includes fifth and sixth characters for anatomic location and complications.

Key Guideline Points

1. Code to highest degree of specificity: Assign the code that reflects the anatomic location (small intestine, large intestine, both, or unspecified) and complication status (rectal bleeding, obstruction, fistula, abscess, other complication, or without complication).
2. Multiple codes for multiple complications: ICD-10-CM Tabular notes indicate that when Crohn’s disease involves multiple complications, assign additional codes to capture each complication. For example, a patient with Crohn’s ileocolitis with both fistula and abscess should be coded K50.813 (fistula) and K50.814 (abscess) — or verify if a combination code applies for the documented encounter.
3. Associated conditions: Code separately any associated extraintestinal manifestations (arthropathy, uveitis, erythema nodosum, PSC) when documented by the provider as related to Crohn’s disease.
4. Active vs. remission: When the provider documents Crohn’s disease “in remission,” assign the appropriate K50.x0 code (without complications, e.g., K50.00, K50.10, K50.80, K50.90). Active disease without specified complication uses K50.x00 structure.
5. Indeterminate IBD: When the provider cannot distinguish between Crohn’s and UC, do not assume either diagnosis. Assign K52.3 (indeterminate colitis) and query the provider for clarification.
6. Crohn’s vs. UC distinction: K50 (Crohn’s disease) and K51 (ulcerative colitis) are mutually exclusive. Do not assign both without clear documentation of co-existing distinct conditions.
7. Sequencing: For inpatient admissions, the condition established after study to be chiefly responsible for the admission should be sequenced as the principal diagnosis. In most Crohn’s flare admissions, K50.x code is principal; complications (fistula, abscess) may be principal if the complication is the primary reason for admission.
8. Surgical complications: Post-surgical complications (anastomotic leak, post-ileostomy complications) may require K91.x codes (postprocedural disorders of digestive system) rather than K50.x codes — review context carefully.

🔢 9. ICD-10-CM Code Set (FY2026)

The following complete code set for Crohn’s disease reflects FY2026 ICD-10-CM (effective October 1, 2025). Codes are organized by anatomic location and complication type.

K50.0 — Crohn’s Disease of Small Intestine

K50.1 — Crohn’s Disease of Large Intestine

K50.8 — Crohn’s Disease of Both Small and Large Intestine (Ileocolitis)

K50.9 — Crohn’s Disease, Unspecified

Associated and Complication Codes

🔎 10. Indexing

The ICD-10-CM Alphabetic Index provides multiple entry points for Crohn’s disease. Coders should verify all Index pathways lead to the same code before assigning:

🏥 11. CPT (2026)

The following CPT codes are most frequently encountered in Crohn’s disease management. Codes reflect CY2026 CPT (American Medical Association).

Endoscopy Procedures

Surgical Procedures

🧾 12. HCPCS (2026)

The following HCPCS Level II codes are used for biologic therapies administered in the outpatient infusion or physician office setting for Crohn’s disease. All codes reflect CY2026 HCPCS Level II as published by CMS.

📚 13. AHA Coding Clinic (Recent Guidance)

The AHA Coding Clinic for ICD-10-CM/PCS provides authoritative guidance on complex coding scenarios. The following represent key guidance principles applicable to Crohn’s disease coding (coders should reference current Coding Clinic issues for exact Q&A wording):

💰 14. HCC / Risk Adjustment (v28)

Under the CMS-HCC Model v28 (effective for payment year 2026), Crohn’s disease and associated conditions map to the following Hierarchical Condition Categories:

✍️ 15. CDI Query Templates

The following query templates are AHIMA/ACDIS-compliant, non-leading, and offer multiple-choice options per AHIMA Practice Brief: Guidelines for Achieving a Compliant Query Practice (2019 Update).

🧑‍⚕️ 16. Treatments (Clinical)

Clinical management of Crohn’s disease follows a treat-to-target strategy as outlined in the ACG Clinical Guidelines for Crohn’s Disease (2018, updated guidance 2024) with the goal of achieving and maintaining deep remission (clinical, endoscopic, and histologic remission).

Medical Management

• Induction of Remission:
  • Mild-moderate disease: Budesonide (9 mg/day) for ileocolonic disease; mesalamine for mild colonic disease
  • Moderate-severe disease: Prednisone 40–60 mg/day (bridge therapy only; not for maintenance); biologic therapy initiation
  • Severe/fulminant: IV corticosteroids (methylprednisolone 40–60 mg/day IV); hospitalization required
• Maintenance of Remission:
  • Immunomodulators (azathioprine, 6-MP, methotrexate) — for steroid-dependent or frequently-relapsing disease
  • Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease
  • Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy
• Biologic Therapy Targets:
  • TNF-α: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC)
  • IL-12/23: Ustekinumab (IV induction, SC maintenance)
  • Integrin: Vedolizumab (IV)
  • IL-23: Risankizumab (IV induction, SC maintenance)
  • JAK inhibition: Upadacitinib (oral)

Surgical Management

Surgery is indicated in approximately 70–80% of patients with Crohn’s disease over their lifetime, per StatPearls. Indications include:

• Medically refractory disease not responding to optimized biologic therapy
• Bowel obstruction from fibrostenotic stricture
• Intra-abdominal abscess not amenable to percutaneous drainage
• Complex perianal fistula (seton placement, diversion)
• Enterocutaneous or enterovesical fistula
• Dysplasia or cancer in Crohn’s colitis
• Free perforation (rare)

Nutritional Therapy

• Exclusive enteral nutrition (EEN) — effective for induction in pediatric Crohn’s; less commonly used in adults
• Partial enteral nutrition — may supplement medical therapy and support nutritional status
• Total parenteral nutrition (TPN) — indicated for severe malnutrition, short bowel syndrome post-resection, or surgical preparation

🎓 17. Patient Education / Summary

The following patient-friendly summary may be adapted for use in patient education materials, discharge instructions, or practice communications. Clinical details should be reviewed and approved by a licensed provider before use with patients.

What Is Crohn’s Disease?

Crohn’s disease is a long-term (chronic) condition that causes inflammation in your digestive tract. Unlike many digestive problems, Crohn’s disease can affect any part of your digestive system — from your mouth to your anus — though it most often affects the end of the small intestine (the ileum) and the beginning of the large intestine (the colon). For more information, visit the Crohn’s & Colitis Foundation.

Key Points for Patients

• It is a chronic condition: Crohn’s disease cannot currently be cured, but it can be managed effectively with the right treatment. Many people with Crohn’s live full, active lives.
• Flares and remission: Crohn’s disease typically follows a pattern of flares (when symptoms are active) and remission (when symptoms improve or disappear). Your care team will work to keep you in remission as long as possible.
• Medications matter: Take prescribed medications as directed, even when feeling well. Stopping biologic therapy or immunosuppressants without medical guidance can trigger a flare.
• Nutrition: There is no single “Crohn’s diet,” but keeping a food diary and working with a registered dietitian can help identify personal trigger foods and maintain adequate nutrition.
• Monitoring: Regular colonoscopies, blood tests, and imaging are important for monitoring disease activity, medication safety, and cancer surveillance (long-standing Crohn’s colitis increases colorectal cancer risk).
• Mental health: Living with a chronic illness can be stressful. Ask your care team about mental health resources and support groups through the Crohn’s & Colitis Foundation Support Community.
• Vaccinations: Patients on biologic or immunosuppressive therapy need specific vaccines (avoid live vaccines). Discuss your vaccination schedule with your gastroenterologist and primary care provider.

When to Seek Immediate Care

Contact your provider or go to the emergency room if you experience:

• Severe abdominal pain or a rigid, board-like abdomen
• High fever (above 101°F / 38.3°C) with abdominal pain
• Significant rectal bleeding or blood in stool
• Signs of bowel obstruction: severe cramping, vomiting, inability to pass gas or stool
• Sudden worsening of symptoms in a patient on biologic therapy (may indicate infection)

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)